Escitalopram - Depression
You are here : Home > Formulary Search > Escitalopram - Depression
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Green
Formulations :
- Tablets
Formulary Status :
Associated Icons :
Restrictions / Comments :
Status 2
Green (see narrative)
Formulations :
- Oral drops
- Oro-dispersible tablets
Formulary Status :
Associated Icons :
Restrictions / Comments :
Important
For use where ordinary tablets are not suitable.
Documentation
PAD Profile
ChemicalSubstance :
Escitalopram
Indication :
Depression
Group Name :
Keywords :
antidepressants, Selective serotonin re-uptake inhibitors, SSRIs
Brand Names Include :
Cipralex
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Traffic Light Entries :
2
Other Indications
Below are listed other indications that Escitalopram is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Depression.
- Amitriptyline hydrochloride
- Bupropion hydrochloride
- Citalopram
- Clomipramine hydrochloride
- Duloxetine hydrochloride
- Esketamine hydrochloride
- Fluoxetine hydrochloride
- Flupentixol
- Fluvoxamine maleate
- Imipramine hydrochloride
- Isocarboxazid
- Lithium - adults
- Lofepramine hydrochloride
- Mianserin hydrochloride
- Mirtazapine
- Moclobemide
- Nortriptyline
- Paroxetine hydrochloride
- Phenelzine sulfate
- Quetiapine
- Reboxetine
- Sertraline
- Tranylcypromine sulfate
- Trimipramine maleate
- Venlafaxine
- Vortioxetine
Committee Recommendations (3)
15 Aug 18 -
Not Set
The Mood Hive and associated local depression and anxiety treatment guidelines have been removed from PAD.
Updated guidelines and resources for treating and managing depression in adults are being developed by Surrey & Borders Partnership. For current advice, in line with NICE guidance, please see the Clinical Knowledge Summaries - link provided below
Updated guidelines and resources for treating and managing depression in adults are being developed by Surrey & Borders Partnership. For current advice, in line with NICE guidance, please see the Clinical Knowledge Summaries - link provided below
GENERIC Escitaloparn has been considered by the PCN and has been assigned a GREEN traffic light status
NOTE - the branded product, Cipralex, was considered BLACK at the PCN in May 2017.
NOTE - the branded product, Cipralex, was considered BLACK at the PCN in May 2017.
The committee recommend that escitalopram could be used as 2nd or 3rd line treatment as part of a choice of antidepressants after generic SSRIs have been prescribed but have not been tolerated or have not been effective and that the recommendations being made are in line with the NHS Surrey Depression and Anxiety Spectrum Care Pathway and NICE guidance